2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
5
Prostatic Neoplasms, Castration-Resistant
1
Prostate Cancer Metastatic
1
Neoplasms
1
Interventions
enzalutamide
20
Abiraterone Acetate
11
Prednisone
7
Docetaxel
7
radium Ra 223 dichloride
6
darolutamide
5
abiraterone
5
apalutamide
3
olaparib
2
niraparib
2
cabazitaxel
2
atezolizumab
2
Pluvicto
2
Nivolumab
2
zimberelimab
1
xentuzumab
1
tasquinimod
1
sacituzumab govitecan
1
sabizabulin
1
quemliclustat
1
pembrolizumab
1
ipatasertib
1
ibrutinib
1
gedatolisib
1
gallium 68 PSMA-11
1
fludrocortisone acetate
1
TVB-2640
1
Standard of Care
1
Rosuvastatin Calcium
1
Radium-223
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms, Castration-Resistant
×
fludrocortisone acetate
×
Clear all
NCT06353386
2026-05-26
MK-5684-01A
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
220 enrolled